TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06216704

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance relaxometry
Description: Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA
Description: DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
Study: NCT05544942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: 1 capsule once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: 1 capsule once a day
Study: NCT05139199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure group
Description: A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
Study: NCT05268393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE-T1D
Description: BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BREATHE-T1D
Description: BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
Study: NCT03978780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
Study: NCT04832009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 20 % in 500 ML Injection
Description: Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
Study: NCT04820205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine and ketamine
Description: Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral chloral hydrate
Description: Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
Study: NCT05597150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
Study: NCT06579534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education strategy
Description: Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
Study: NCT04942665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine green
Description: Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT Endoscopic Fluorescence
Description: The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PINPOINT Endoscopic Fluorescence
Description: The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
Study: NCT05131815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Description: Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
Study: NCT06188624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2922 for injection
Description: TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
Study: NCT05544175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NEUROMOdulation pain therapy in combination with intensive physiotherapy
Description: Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients.
Study: NCT06216704

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA
Description: DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: pQCT
Description: pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.

Intervention type: DIAGNOSTIC_TEST
Intervention: pQCT
Description: pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
Study: NCT05577832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap Technique
Description: In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ShotBlocker Technique
Description: In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Technique
Description: Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
Study: NCT05415592

Intervention type: DEVICE
Intervention: DePuy Synthes Radial Head Replacement System
Description: DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
Study: NCT05651269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib Dose: 150 mg/day Mode of administration: oral
Description: milciclib plus gemcitabine
Study: NCT06054516

Intervention type: DIAGNOSTIC_TEST
Intervention: 13C-enriched pyruvate
Description: Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
Study: NCT05138068

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy
Description: Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
Study: NCT04696952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Zopiclone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05918107

Intervention type: DRUG
Group type: OTHER
Intervention: PM8002
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: IV infusion
Study: NCT05285397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: Subcutaneous injection of GLP-1 agonist
Study: NCT06095999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity
Description: The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
Study: NCT06202677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-guided program on obsessive compulsive disorder
Description: This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided program on cooperation
Description: This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
Study: NCT06356012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure
Description: Active comparator group will be treated with LEEP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loop Electrosurgical Excision Procedure
Description: Active comparator group will be treated with LEEP.
Study: NCT05500391

Intervention type: OTHER
Group type: OTHER
Intervention: Oncological Follow-up
Description: Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological Follow-up
Description: Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
Study: NCT04863118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training in shallow water and dry land
Description: Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity training in shallow and deep water
Description: Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water.